Latest news
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/unite4tb-4.png)
![](https://amr-accelerator.eu/wp-content/uploads/2022/02/primavera-1.png)
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/unite4tb-4.png)
![](https://amr-accelerator.eu/wp-content/uploads/2024/04/Asset-1.png)
![](https://amr-accelerator.eu/wp-content/uploads/2020/09/Circle_ABDirect.png)
![](https://amr-accelerator.eu/wp-content/uploads/2022/02/primavera-1.png)
Interviews
![](https://amr-accelerator.eu/wp-content/uploads/2023/11/Respiris_interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2023/01/IHI_Interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2022/06/PRIMAVERA_Interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2021/11/IMI_ERA4TB.jpg)
Newsletters
From the partners
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/BEAM-Alliance-495x400.png)
21/10/21 – How the EU Pharmaceutical Strategy could help prevent the next pandemic
![](https://amr-accelerator.eu/wp-content/uploads/2021/08/DZIF-495x400.png)
![](https://amr-accelerator.eu/wp-content/uploads/2021/04/BioVersys-495x400.png)
14/04/21 – BioVersys receives €20 million in EU financing to support development of new antibiotics
![](https://amr-accelerator.eu/wp-content/uploads/2021/03/TB-Alliance-495x400.png)
30/03/21 – Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis
![](https://amr-accelerator.eu/wp-content/uploads/2021/02/BIOASTER-495x400.png)
ERA4TB Newsletter – July 2021
AMR Accelerator Newsletter – May 2021
ERA4TB Newsletter – May 2021
RespiriNTM & -TB Newsletter – April 2021